Notably, these in vivo differences include a slower clearance than regular insulin, attributable largely to diminished IR mediated clearance, to a hepato-adipose tissue predominance in insulin action with relative sparing of skeletal muscle insulin action, and for a lesser propensity to cause hypoglycemia, a frequent complication of conventional insulin therapy. This evidence concerns the gene INS and Hypoglycemia.